China's Simcere Signs Novel Licensing Agreement Covering U.S.-based OSI Pharmaceutical's Cancer Drug

SHANGHAI - Simcere Pharmaceutical, a leading Chinese drug and biotech firm, has signed an agreement with the U.S.-based OSI Pharmaceutical to license OSI's cancer treatment candidate OSI-930 in China